Organization
Genmab
40 clinical trials
3 abstracts
Clinical trial
A Phase 1 Dose Finding and Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Clinical Activity of Immunoradiotherapy Combinations as a Treatment Option in Subjects With Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A First-In-Human, Open-Label, Dose Escalation Trial to Evaluate the Safety and Antitumor Activity of GEN1057 in Subjects With Malignant Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2027-10-31
Clinical trial
A Phase 2 Exploratory, Multicenter, Open-Label Trial to Determine the Safety and Preliminary Clinical Activity of GEN1046 in Combination With Anticancer Agents in Subjects With Advanced Endometrial CancerStatus: Withdrawn, Estimated PCD: 2028-04-01
Clinical trial
Efficacy and Safety of Epcoritamab Monotherapy and in Combination With Lenalidomide as First-line Therapy for Anthracycline-ineligible Diffuse Large B-Cell Lymphoma Patients, an Open-label, Randomized, Multicenter, Global Phase 2 TrialStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)Status: Recruiting, Estimated PCD: 2029-03-31
Clinical trial
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination Pembrolizumab Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint InhibitorStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)Status: Recruiting, Estimated PCD: 2029-11-15
Clinical trial
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Status: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
Phase 1b/2, Open-Label Trial to Evaluate Safety and Preliminary Efficacy of Epcoritamab As Monotherapy or Combined With Standard-of-Care Therapies in Chinese Subjects With B-Cell Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-12-13
Clinical trial
First-in-Human, Open-label, Dose-Escalation Trial With an Expansion Cohort to Evaluate the Safety of GEN1053 as Monotherapy in Subjects With Malignant Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2026-09-01
Clinical trial
Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A Phase 1/2, Open-Label, Dose-Escalation Trial With Expansion CohortsStatus: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2029-12-31
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2032-11-26
Clinical trial
A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell NeoplasmsStatus: Recruiting, Estimated PCD: 2027-06-18
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
A First-in-Human, Open-label, Dose-finding Trial to Evaluate the Safety and Antitumor Activity of GEN1056 in Subjects With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-05-31
Clinical trial
A Phase 1 Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GEN1042 Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Japanese Subjects With Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2026-05-29
Clinical trial
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) When Administered in the Outpatient SettingStatus: Recruiting, Estimated PCD: 2027-08-29
Clinical trial
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's SyndromeStatus: Recruiting, Estimated PCD: 2029-06-01
Clinical trial
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Dose-Escalation, Randomized Phase I/II Trial of Zalutumumab - a Human Monoclonal Anti-EGF Receptor Antibody - With or Without Irinotecan Chemotherapy in Cetuximab Refractory Colorectal Cancer Patients Who Have Failed Standard Chemotherapy and Progressed During or Within 3 Months of Stopping Cetuximab-Based TherapyStatus: Terminated, Estimated PCD: 2009-04-01
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid TumorsStatus: Terminated, Estimated PCD: 2021-10-29
Clinical trial
Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion CohortsStatus: Terminated, Estimated PCD: 2022-11-21
Clinical trial
An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Advanced Stage (IIA-IVB) Cutaneous T-cell LymphomaStatus: Completed, Estimated PCD: 2004-06-29
Clinical trial
Expanded Access Program (EAP) to Provide Epcoritamab (GEN3013) to Eligible Patients With Relapsed or Refractory Large B-cell LymphomaStatus:
Clinical trial
An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Persistent Early Stage (IA-IIA) Cutaneous T-Cell LymphomaStatus: Completed, Estimated PCD: 2004-05-05
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Clinical Trial of Anti-CD4 Receptor Human Monoclonal Antibody (HuMax-CD4) in Patients With Active Rheumatoid Arthritis Failing Treatment With Methotrexate and TNF-alpha Blocking AgentsStatus: Terminated, Estimated PCD: 2003-03-31
Clinical trial
An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic Profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Non-curable Patients With SCCHNStatus: Completed, Estimated PCD: 2011-07-01
Clinical trial
An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination With Radiotherapy, in Patients With Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum Based ChemotherapyStatus: Terminated, Estimated PCD: 2010-10-01
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1029 in Patients With Malignant Solid TumorsStatus: Terminated, Estimated PCD: 2021-10-12
Clinical trial
An Open, Single Dose Escalation Study Followed by a Multiple Dose Extension of Anti-EGF Receptor Human Monoclonal Antibody (Zalutumumab) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)Status: Completed, Estimated PCD: 2005-01-12
Clinical trial
An Open Label Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Best Supportive Care, in Patients With Non-Curable Squamous Cell Carcinoma of the Head and Neck Who Have Failed Standard Platinum-based Chemotherapy.Status: Completed, Estimated PCD: 2011-08-01
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid TumorsStatus: Completed, Estimated PCD: 2021-11-12
Clinical trial
Open-label, Dose-escalation Trial to Evaluate the Safety and Pharmacokinetics of GEN1046 in Japanese Subjects With Advanced Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-11-12
Clinical trial
First-In-Human, Open-Label, Dose Escalation Trial With Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of GEN1055 as Monotherapy and as Combination Therapy in Subjects With Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2028-05-01
Clinical trial
A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Abstract
Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.Org: Lymphoma Service, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Vejle Hospital, Universitair Ziekenhuis Gent, Ronald Reagan University of California Los Angeles Medical Center,
Abstract
Spatial genomics to reveal an immunosuppressive tumor microenvironment after chemoradiation in head and neck cancer patients.Org: Duke University Medical Center/Duke Cancer Institute, Genmab, Genmab Utrecht, Genmab US Inc., Janssen Research and Development LLC, Raritan, NJ,
Abstract
Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.Org: University of Michigan Comprehensive Cancer Center, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, MSC National Research Institute of Oncology, Kraków, Poland, Sir Charles Gairdner Hospital,
Clinical trial
Phase 1b/2, Open-Label Trial to Evaluate Safety and Preliminary Efficacy of Epcoritamab As Monotherapy or Combined With Standard-of-Care Therapies in Chinese Subjects With B-Cell Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-12-13